Skip to main content
TipRanks
Go Ultimate75% OFF

Phreesia (0A23) AI Stock Analysis

0 Followers
GB:0A23

Phreesia

(LSE:0A23)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Cash GenerationStrong and rising operating and free cash flow indicate that Phreesia is increasingly converting its healthcare software operations into internally funded resources. This supports debt reduction, continued product investment, and greater resilience without relying as heavily on external financing.
Negative Factors
Thin Profitability CushionDespite the recent profitability inflection, Phreesia's earnings cushion remains narrow relative to its operating scale. If growth slows or costs rise, modest margin levels could compress quickly, limiting retained earnings and reducing the company's ability to absorb execution setbacks.

Phreesia (0A23) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:0A23-64.91%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$795.75M
Dividend Yield
―
Average Volume (3M)
199
Price to Earnings (P/E)
73.8
Beta (1Y)
0.10
Revenue Growth
12.93%
EPS Growth
―
Country
UK
Employees
1,789
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Phreesia Business Overview & Revenue Model

Company Description

Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake proc...

Phreesia Earnings Call Summary

Earnings Call Date:Sep 02, 2026(Q2-2027)|% Change Since:-64.91%|Next Earnings Date:Dec 02, 2026
Earnings Call SentimentPositive

The call was strongly constructive, with 10% year-over-year revenue growth, substantial adjusted EBITDA expansion, positive net income for the fifth consecutive quarter, continued positive cash flow, more than $23 million of debt reduction, and reaffirmed fiscal 2027 guidance. AccessOne, Provider Connect, the GLP-1 campaign, and AI initiatives showed encouraging momentum. The main challenges were sequential declines tied to payment-processing seasonality, provider economic strain, pricing moderation, and some earlier volume weakness beyond seasonality.

Positive Updates

Revenue Growth in Line with Expectations
Second-quarter revenue was $129.5 million, up 10% year-over-year, with revenue growth and profitability expansion described as in line with expectations.

Negative Updates

Sequential Revenue Decline from Payment Seasonality
Total revenue declined approximately 1% sequentially from the first quarter, driven primarily by legacy payment processing revenue. Management noted that payment processing revenue is typically highest in the first fiscal quarter because of health plan deductible resets.

Company Guidance

For fiscal 2027, Phreesia is maintaining its revenue outlook at a range of $510 million to $520 million, including approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027; adjusted EBITDA guidance remains at a range of $125 million to $135 million, with the restructuring plan expected to result in meaningful annualized run rate expense savings, and AHSC growth expected in the mid-single-digit percentage range and total revenue per AHSC growth in the low single-digit percentage range.

Phreesia Risk Analysis

Phreesia disclosed 57 risk factors in its most recent earnings report. Phreesia reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Phreesia Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A23 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
WAYWAY76Outperform$5.41B39.863.41%―21.43%9.80%
CCLDCCLD66Neutral$94.88M17.2724.48%―14.86%214.99%
EVHEVH58Neutral$546.30M-1.07-129.54%―14.06%-189.46%
AMWLAMWL57Neutral$195.28M-3.30-25.49%―-20.30%52.30%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HCATHCAT51Neutral$105.09M-0.49-128.24%―-13.88%-78.38%

* Healthcare Sector Average

Performance Comparison

0%100%200%GB:0A23CCLDEVHHCATAMWLWAYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A23 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A23Phreesia10.00-18.50-64.91%
CCLDCarecloud, Inc.2.23-0.75-25.17%
EVHEvolent Health Inc.4.830.8320.75%
HCATHealth Catalyst1.38-0.79-36.41%
AMWLAmerican Well Corporation11.347.32182.09%
WAYWaystar Holding Corp.28.11-6.76-19.39%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.